Merck Becomes Member of the Worldwide Innovative Network in Personalized Cancer Medicine
Posted: Thursday, June 15, 2017
June 15, 2017 06:00 AM Eastern Daylight Time
PARIS & DARMSTADT, Germany--(BUSINESS WIRE)--Worldwide Innovative Network in Personalized Cancer Medicine - WIN Consortium proudly announces today that Merck, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, becomes a member of the WIN Consortium. WIN is a network of 40 academic institutions and industries across the globe, focusing on new generation biomarker-driven therapeutic clinical trials and biomarker discovery programs conducted worldwide, aiming to significantly impact the survival of cancer patients. Merck reinforces WIN’s pharmaceutical industry membership. WIN’s global collaborative research strategy will be presented at the WIN 2017 Symposium in Paris, France, on 26-27 June.
Merck’s strong corporate commitment to the development of drugs using a precision medicine approach, coupled with the company’s wide breadth of experience in the development of oncology therapeutics, its company’s goals and capabilities are strategically aligned with the mission of WIN.
About the WIN Consortium
The WIN Consortium is a global network of 40 leading organizations from the academic, pharmaceutical, biotechnology and patient advocacy sectors working to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials, the most promising advances in genomic-based cancer research. WIN is a non-governmental, not-for-profit organization headquartered in Paris.
For further information, please visit www.winconsortium.org.
Director Operational Team
Vladimir Lazar, Tel: + 33 66 109 15 22
Chief Scientific and Operating Officer